- Alabama AG Steve Marshall led a coalition of 20 state AGs in sending a letter to Secretary of State Marco Rubio raising national security concerns about the pharmaceutical supply chain and the sourcing of dangerous ingredients used in compounded GLP-1 medications, including semaglutide, tirzepatide, and retatrutide.
- The letter cites that in September 2025, the Food and Drug Administration (FDA) authorized the creation of a “Green List” of suppliers, which has given Chinese suppliers the ability to “ship unapproved knock-off products to the United States without detention or inspection.” The AGs allege that the Green List has become a “laundering channel” and should require more oversight.
- The AGs cite an instance in which Harbin Jixianglong Biotech Co., Ltd (Harbin) was found to have purchased knock-off semaglutide from a non-Green List facility that was not registered with the FDA. Since Harbin was on the Green List, it was only after an on-site inspection that it was discovered that Harbin had repackaged and relabeled the non-Green List products under Harbin’s name, changed the manufacturing and retest dates, and distributed them to the United States.